FDA would take charge of hemp cannabinoid products under new federal bill

What does this do?

HR 7212 creates a new federal regulatory system for hemp-derived cannabinoid products such as CBD oils, edibles, vapes, and lotions, ending the current legal gray area. The FDA would set safety standards, define which products are permitted, and ban those with too much intoxicating content, fully synthetic cannabinoids, or transdermal bloodstream absorption. Edibles and drinks would face per-serving and per-package limits on intoxicating content, while vapes would require prefilled sealed cartridges and FDA-approved ingredients only.

Who does it affect?

Hemp product manufacturers would need to register facilities, list products, and meet testing and labeling requirements, with smaller businesses among those affected. Retailers would be required to enforce a minimum purchase age of 21, and foreign companies selling into the US market would face inspection requirements.

Why does it matter?

All products would require labels disclosing cannabinoid content, health warnings, allergen information, and a QR code linking to lab test results, giving consumers more consistent product information. Companies that commit serious violations could face criminal penalties of up to 10 years in prison.

What does it cost, and who pays?

• Criminal penalty up to 10 years prison
• Applies to serious violations only